Ubix Therapeutics

Ubix Therapeutics, Inc. develops novel anti-cancer drugs based on Proteolysis Targeting Chimera
(PROTAC) platform technology.


PROTAC is a technology that utilizes the UPS system, an intracellular purification system. PROTAC is a bifunctional molecule where “ligand”, which binds to target protein, and “binder”, which binds to E3 ubiquitin ligase, are connected by a linker. In other words, PROTAC is a powerful inhibitor technology that enables target protein degradation and consequent therapeutic effects by placing a disease-related target protein nearby E3 ligase, which can then initiate the protein degradation system.


Ubix Therapeutics, Inc. is focused on developing cancer immunotherapy based on experience and expertise in Cell Signaling Pathway and Epigenetics research. We are aware that in order to do so successfully, close cooperation with our partners are the most important, and thus we are consistently looking forward to form partnerships in various R&D and business fields.
Based on mutualistic partnerships and outstanding technology capable of international competition, Ubix Therapeutics, Inc. will jump beyond the border to become a world-class bio company.



#303 Seoul Bio Hub, 117-3, Hoegi-ro, Dongdaemun-gu, Seoul, Republic of Korea (02455)